Clinical Trial Detail

NCT ID NCT03333616
Title Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Dana-Farber Cancer Institute
Indications

germ cell cancer

penile cancer

urinary bladder cancer

adrenocortical carcinoma

urinary system cancer

prostate cancer

Therapies

Ipilimumab + Nivolumab

Age Groups: adult senior

No variant requirements are available.